Morgan Stanley Xilio Therapeutics, Inc. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 221,905 shares of XLO stock, worth $210,809. This represents 0.0% of its overall portfolio holdings.

Number of Shares

221,905

Previous 127,265 74.36%

Holding current value

$210,809

Previous $69,000 246.38%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.55 - $1.08 $52,052 - $102,211	94,640 Added 74.36%	221,905 $239,000
Q4 2023 Feb 13, 2024	BUY	$0.5 - $2.5 $50,500 - $252,500	101,000 Added 384.54%	127,265 $69,000
Q3 2023 Nov 15, 2023	SELL	$2.11 - $2.9 $1,584 - $2,177	-751 Reduced 2.78%	26,265 $55,000
Q2 2023 Aug 14, 2023	SELL	$2.55 - $3.46 $8,983 - $12,189	-3,523 Reduced 11.54%	27,016 $70,000
Q1 2023 May 15, 2023	BUY	$2.66 - $4.28 $13,108 - $21,091	4,928 Added 19.24%	30,539 $96,000

Q4 2022 Feb 14, 2023	BUY	$1.97 - $2.72 $36,978 - $51,057	18,771 Added 274.43%	25,611 $68,000
Q3 2022 Nov 14, 2022	SELL	$2.07 - $3.44 $413 - $688	-200 Reduced 2.84%	6,840 $20,000
Q2 2022 Oct 27, 2022	BUY	$2.08 - $7.2 $10,266 - $35,539	4,936 Added 234.6%	7,040 $20,000
Q2 2022 Aug 15, 2022	BUY	$2.08 - $7.2 $10,266 - $35,539	4,936 Added 234.6%	7,040 $20,000
Q1 2022 Oct 27, 2022	SELL	$6.63 - $16.05 $32,725 - $79,222	-4,936 Reduced 70.11%	2,104 $14,000
Q1 2022 May 13, 2022	BUY	$6.63 - $16.05 $7,067 - $17,109	1,066 Added 102.7%	2,104 $14,000
Q4 2021 Feb 14, 2022	BUY	$9.69 - $25.11 $10,058 - $26,064	1,038 New	1,038 $17,000

Others Institutions Holding XLO

# of Institutions

Shares Held

10M

Call Options Held

Put Options Held

View Full List

About Xilio Therapeutics, Inc.

Ticker XLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,471,600
Market Cap $26.1M
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...

More about XLO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account